Pascal Bamford - 29 Aug 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Clinical Officer
Signature
/s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
29 Aug 2024
Net transactions value
$0
Form type
4
Filing time
03 Sep 2024, 21:41:14 UTC
Next filing
21 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Award $0 +40,000 +48% $0.000000 122,758 29 Aug 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units shall vest in full on the second anniversary of the first day of the month subsequent to the date of grant.
F2 Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.